Literature DB >> 8395968

Absence of Epstein-Barr virus in carcinoma of the cervix.

D A Hilton1, L J Brown, J H Pringle, H Nandha.   

Abstract

BACKGROUND: Cervical epithelium is known to contain receptors for Epstein-Barr virus (EBV) and is a recognized site of viral shedding. Recent cases of nasopharyngeal carcinoma have been associated with cervical carcinoma, leading to speculation of a possible etiologic link between EBV and cervical carcinoma.
METHODS: This study investigates the presence of EBV in 24 cases of invasive cervical carcinoma (9 adenocarcinomas and 15 squamous cell carcinomas) and 10 cases of cervical intraepithelial neoplasia (4 adenocarcinomas in situ and 6 squamous: 3 CIN II, 3 CIN III), using in situ hybridization.
RESULTS: In one case, EBV was demonstrated in infiltrating lymphocytes adjacent to tumor epithelium, but in no cases did the malignant epithelium show the presence of EBV.
CONCLUSIONS: These results suggest that EBV does not play a role in the etiology of cervical carcinoma, although further studies are needed.

Entities:  

Mesh:

Year:  1993        PMID: 8395968     DOI: 10.1002/1097-0142(19930915)72:6<1946::aid-cncr2820720625>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Co-presence of human papillomaviruses and Epstein-Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients.

Authors:  Hamda Al-Thawadi; Ishita Gupta; Ayesha Jabeen; Faruk Skenderi; Tahar Aboulkassim; Amber Yasmeen; Mohammed I Malki; Gerald Batist; Semir Vranic; Ala-Eddin Al Moustafa
Journal:  Cancer Cell Int       Date:  2020-08-03       Impact factor: 5.722

2.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28

Review 3.  The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.

Authors:  Semir Vranic; Farhan Sachal Cyprian; Saghir Akhtar; Ala-Eddin Al Moustafa
Journal:  Front Oncol       Date:  2018-04-17       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.